Mitochondrial dysfunction in sIBM patients. by Yoshitsugu Oikawa (9721356)

CFD-DEM Coupling Simulation and Cross-Scale Correlation Analysis of a Liquid-Containing Gas–Solid Spouted Fluidized Bed Reactor by Delong Feng (9075738)

“…When μ < 50 mPa·s, higher viscosity increases large agglomerates and decreases small agglomerates. …”

Saturation Kinetics in Phenolic O–H Bond Oxidation by a Mononuclear Mn(III)–OH Complex Derived from Dioxygen by Gayan B. Wijeratne (1776322)

“…Saturation kinetics were observed for phenol oxidation, implying an initial equilibrium prior to the rate-determining step. On the basis of a collective body of evidence, the equilibrium step is attributed to the formation of a hydrogen-bonding complex between [Mn^III(OH)­(dpaq)]⁺ and the phenol substrates.…”

Saturation Kinetics in Phenolic O–H Bond Oxidation by a Mononuclear Mn(III)–OH Complex Derived from Dioxygen by Gayan B. Wijeratne (1776322)

“…Saturation kinetics were observed for phenol oxidation, implying an initial equilibrium prior to the rate-determining step. On the basis of a collective body of evidence, the equilibrium step is attributed to the formation of a hydrogen-bonding complex between [Mn^III(OH)­(dpaq)]⁺ and the phenol substrates.…”

PAC-1 activation counteracts impaired NSCs under hypoglycaemic <i>milieu via</i> the PKA-dependent pathway. by Shiva Mansouri (2838086)

Fabrication of (a) schematic diagram of solid oxide fuel cell using GDC/BNMO/LSCO and (b) shows the cell components that serve as structural materials. by Nacer Badi (14046883)

Characteristics of census tracts that are projected to have high (groups: 250-399 and 400+) and low (groups: 50-99 and 100-249) MHC utilization for COVID-19 vaccination before Marc... by Fatih Gezer (21485468)

Depletion of SAMHD1 causes cellular R-loop accumulation. by Kiwon Park (6492266)

Depletion of SAMHD1 induces cell cycle delay and spontaneous DNA damage response. by Kiwon Park (6492266)

The effects of TDBP-TAZTO (5 and 50 mg/kg) on spatial learning and memory in rats in the Morris water test. by Liang Ye (6646)

“…Data ate expressed as mean ± SE (n = 10/group). ^a<i>p</i> < 0.05, TDBP-TAZTO 5 mg/kg group vs. control group; ^b<i>p</i> < 0.05, TDBP-TAZTO 50 mg/kg group vs. control group.…”

Depletion of SAMHD1 induces R-loop-mediated genome instability and cellular DNA damage response. by Kiwon Park (6492266)

The inactivation of the acetyl-CoA acyltransferase 1 enzyme by the novel putative miRNA Oeu124369 leads to a decrease in Acetyl-CoA production and additionally, the deactivation of... by Mohammad Hossein Pakdel (19837942)

(A–D) Representative immunoblots for the reporter assays shown in Fig 4A–D. by Lorenza Cutrone (21144285)

Synthesis and Spectroscopic Investigation of a Series of Push–Pull Boron Dipyrromethenes (BODIPYs) by Sunting Xuan (1494469)

“…All BODIPYs were nontoxic in the dark (IC₅₀ > 200 μM) and showed low phototoxicity (IC₅₀ > 100 μM, 1.5 J/cm²) toward human HEp2 cells. …”

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”